To acquire R&D centre at Saint-Julien-en-Genevois, France and add drug discovery and preclinical development capabilities in biologics and antibody drug conjugate

Jubilant Biosys Innovative Research Services, Singapore (JBIRSPL), a subsidiary of Jubilant Biosys, a wholly owned subsidiary of Jubilant Pharmova, has executed the transaction definitive agreements with Pierre Fabre, and its affiliate entities (PF), for JBIRSPL to acquire 80 per cent equity capital in JASMIN (new company incorporated by PF in France, as a Societe par Actions Simplifiee (SAS)), with remaining 20 per cent retained by PF.

At closing of the transaction, JASMIN shall acquire Pierre Fabre’s R&D Centre (including R&D Site and R&D activities) at Saint-Julien-en-Genevois, France, and JBIRSPL would also execute a Shareholders’ Agreement and other transition agreements with PF.

Giuliano Perfetti, CEO and MD, Jubilant Biosys said, “We are thrilled to have reached this strategic agreement with Pierre Fabre. Our R&D site in Saint-Julien-en-Genevois will serve as a Center of Excellence for biologics and ADCs, located at the heart of Europe. This expansion strengthens our presence and fosters collaboration with both biotech and large pharma companies in Europe and the USA. By combining the scientific expertise in biologics and ADCs at Saint-Julien-en-Genevois with the capabilities of 1,200 scientists in India we establish a comprehensive service offering for accelerated delivery of early chemistry, discovery biology, DMPK, integrated drug discovery and CDMO for intermediates and APIs. With this strategic move, Jubilant Biosys Limited advances its "CRDMO Partner in Science" strategy and reinforces its commitment to delivering innovative solutions to global pharmaceutical customers.”